Navigation Links
Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
Date:4/29/2009

n the U.S. and an estimated 246 million adults worldwide.(i,ii) Approximately 90-95 percent of those affected have type 2 diabetes. Diabetes is the fifth leading cause of death by disease in the U.S. and costs approximately $174 billion per year in direct and indirect medical expenses.(iii)

According to the Centers for Disease Control and Prevention's National Health and Nutrition Examination Survey, approximately 60 percent of people with diabetes do not achieve their target blood sugar levels with their current treatment regimen.(iv) In addition, 85 percent of type 2 diabetes patients are overweight and 55 percent are considered obese.(v) Data support that weight loss (even a modest amount) supports patients in their efforts to achieve and sustain glycemic control.(vi,vii)

About BYETTA(R) (exenatide) injection

BYETTA is the first and only FDA-approved incretin mimetic for the treatment of type 2 diabetes. BYETTA exhibits many of the same effects as the human incretin hormone glucagon like peptide-1 (GLP-1). GLP-1 improves blood sugar after food intake through multiple effects that work in concert on the stomach, liver, pancreas and brain. BYETTA is approved by the FDA for use by people with type 2 diabetes who are unsuccessful at controlling their blood sugar levels. BYETTA is an add-on therapy for people currently using metformin, a sulfonylurea, or a thiazolidinedione. BYETTA provides sustained A1C control and low incidence of hypoglycemia when used with metformin or a thiazolidinedione, with potential weight loss. BYETTA is not a weight loss product. BYETTA was approved in April 2005 and has been used by more than one million patients since its introduction. For full prescribing information, visit www.BYETTA.com.

Important Safety Information for BYETTA

BYETTA improves glucose (blood sugar) control in adults with
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
4. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
5. Lilly and Glenmark Pharmaceuticals Announce License Agreement
6. Lilly Receives NCQA Design Certification for Depression Care Management Program
7. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
8. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
9. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
10. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement
11. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... Chief Executive Officer, Doug Godshall , is scheduled ... Conference at 8:30 a.m. EDT on Thursday, August 13, ... at the InterContinental Boston. A live webcast ...
(Date:8/4/2015)... Aug. 04, 2015 ... the addition of the "MRI Systems Market ... Operational Efficiency, with Growth Driven by Developing Economies" ... Systems Market to 2020 - Focus on Patient ... Developing Economies" discusses the market, competitive landscape, and ...
(Date:8/4/2015)...  Dr. Keesha Ewers of The ... of flibanserin, or what is being touted as ... decreased female sexual desire back several decades. Diminished ... addressing libido as a singular symptom with a ... Photo - http://photos.prnewswire.com/prnh/20150804/254705 ...
Breaking Medicine Technology:HeartWare Presentation At The Canaccord Genuity 35th Annual Growth Conference To Be Webcast 2Global MRI Systems Market Outlook to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5
... Conn., Oct. 6 The Hedgeye Risk Management Healthcare team, led ... Conference Call, "Aging of America: Demographics of Demand and Profits in ... long tail of demographics, why 1994-2002 was so good, and why ... device demand, and the outlook for hip, knee, and spine device ...
... Oct. 6 Roxane Laboratories, Inc. announced today ... (ANDA) for Losartan Potassium Tablets USP, 25mg, 50mg ... Hydrochlorothiazide Tablets, 50mg/12.5mg and 100mg/25mg by the U.S. ... for immediate shipment to wholesalers and pharmacies nationwide. ...
Cached Medicine Technology:Aging of America: Demographics of Demand and Profits in Healthcare 2Roxane Laboratories, Inc. Announces the Launch of Losartan Potassium Tablets USP and Losartan Potassium and Hydrochlorothiazide Tablets 2
(Date:8/4/2015)... ... August 04, 2015 , ... An article published July 27th by ... viable method for encouraging people to lose weight. Specifically the study compared control patients ... loss success, adding a financial incentive to the overall incentive of increased health. According ...
(Date:8/4/2015)... ... August 04, 2015 , ... PerceptiMed, ... Richard Carmona, M.D., M.P.H., FACS, to its Board of Directors effective August 1, ... lives," Dr. Carmona said. "I strongly believe in the mission of the company ...
(Date:8/4/2015)... ... August 04, 2015 , ... One of the nation’s leading experts ... new book, The Pain Antidote , which provides strategies for people who suffer ... Center’s Chronic Pain Treatment Program, wrote the book in conjunction with Katherine Ketcham, an ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... immunizations, especially those entering kindergarten. All required immunizations are covered for members under ... means that children who aren’t caught up with their immunizations may not be ...
(Date:8/4/2015)... Hills, CA (PRWEB) , ... August 04, 2015 ... ... personal consultation complete with full examination now offered by the world renowned ... more beautiful aesthetic facial appearance through cosmetic surgery techniques helps individuals to achieve ...
Breaking Medicine News(10 mins):Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 2Health News:Dr. Richard Carmona, 17th Surgeon General of the United States, Joins PerceptiMed, Inc.’s Board of Directors 3Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3
... According to the findings of a UCSF study to ... journal "Obstetrics and Gynecology," the risk of miscarriage in ... // or chromosomal abnormalities is lower than previously believed. ... common prenatal tests performed during the first and second ...
... a person grows old, the functioning of his lungs weakens. According ... ,An 8-year study was conducted on 670 men, 45 – 86 ... of long-standing anger at the beginning of the project had notably ... study is one of the first to show prospectively that hostility ...
... turn out to be the worst enemy for asthmatic ... response to air pollution says a recent study.// This ... chronic cough, phlegm production (bronchitis) and dog & cat ... preventive medicine at the University of Southern California's Keck ...
... colon polyps to half, it doubles the risk of serious ... studies published in the Aug. 31 issue of The New ... M.D., Ph.D., and John D. Potter, M.B., Ph.D., of the ... ,"These two trials provide strong evidence that among patients ...
... Physical activity after a high-fat meal not only reverses the ... //of these same arteries compared to before the meal, according ... in the European Journal of Applied Physiology, are part of ... body after the meal -- also known as the postprandial ...
... brain areas preoperative brain could effectively alter the outcome ... appear in the September issue of Radiology, states that ... the brain with functional magnetic resonance imaging (fMRI), could ... effectively, and could also reduce the risk of damaging ...
Cached Medicine News:Health News:Prenatal Test and Miscarriage 2Health News:Prenatal Test and Miscarriage 3Health News:Dogs aggravate asthma in kids 2Health News:Celebrex- pros and cons 2Health News:A Serving of Exercise After That Saturated Fat 2Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 2Health News:fMRI Prior to surgery Could Help In Outcome Of Tumor Surgery 3
Inquire...
Inquire...
Premier pouches provide the ultimate in skin protection with our long wearing Flextend skin barriers and superior comfort with our soft and silky ComfortWear panels....
... APTT-based kit for the screening of factor-V-related ... of the test for the factor V:Q506 ... plasma with an excess of V-DEF Plasma ... to discriminate between heterozygous and homozygous factor ...
Medicine Products: